Lenalidomide plus bendamustine-rituximab does not overcome the adverse impact of TP53 mutations in mantle cell lymphoma
Sign Up to like & getrecommendations! Published in 2018 at "Haematologica"
DOI: 10.3324/haematol.2018.194399
Abstract: TP53 mutations are associated with significant poorer outcomes in mantle cell lymphoma (MCL), and new treatment strategies are highly warranted. Lenalidomide has shown high efficacy in MCL; however, there is no knowledge of its effect… read more here.
Keywords: plus bendamustine; lenalidomide plus; mantle cell; tp53 ... See more keywords